mrna-1647
Vaccineexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Nov 13, 2017 (NCT03382405)
Timeline
Indications
Mechanism of action
- CytomegalovirusImmunity, active
Cytomegalovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06133010 | Phase 2 | Jan 18, 2024 | Moderna Therapeutics |
| NCT05683457 | Phase 2 | Apr 5, 2023 | Moderna Therapeutics |
| NCT05575492 | Phase 1/Phase 2 (Phase 2) | Nov 7, 2022 | Moderna Therapeutics |
| NCT05397223 | Phase 1 | May 24, 2022 | Moderna Therapeutics |
| NCT05105048 | Phase 1 | Nov 8, 2021 | Moderna Therapeutics |
| NCT05085366 | Phase 3 | Oct 26, 2021 | Moderna Therapeutics |
| NCT04975893 | Phase 2 | Jun 18, 2021 | Moderna Therapeutics |
| NCT04232280 | Phase 2 | Dec 23, 2019 | Moderna Therapeutics |
| NCT03382405 | Phase 1 | Nov 13, 2017 | Moderna Therapeutics |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Moderna Therapeutics | For profit | 9 | 9 | 3 | 2017 |
1 organizations
Page 1 / 1